|Articles|November 16, 2020
- Pharmaceutical Executive-11-01-2020
- Volume 40
- Issue 11
Pharmaceutical Executive, November 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 5 years ago
Synthetic Biology and the Environmentabout 5 years ago
Measuring Pharma’s Wider Mandateabout 5 years ago
Patients as the North Starabout 5 years ago
A Rare-Disease Must? Building Long-Term Relationshipsabout 5 years ago
Making Remote Work a Success Beyond COVIDabout 5 years ago
CRISPR for Diversity, and Humanity’s, Sakeabout 5 years ago
Expediting the Cancer Treatment Pathabout 5 years ago
Vaccine Authorization, Distribution Raise Multiple Challengesabout 5 years ago
EU Leaders in High-Stakes Gamble on COVID ResponsesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
3
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
4
Taming the Complexity of CGT Commercialization: 5 Keys to a Workable Operating Model
5